MAT2203

About Matinas Biopharma

Matinas BioPharma's mission is to overcome critical drug delivery challenges through its Lipid Nano-Crystal (LNC) platform, which facilitates oral, intracellular delivery of complex therapeutics. Its primary achievement is the advancement of MAT2203, an oral formulation of the potent but toxic antifungal amphotericin B, into Phase 2/3 clinical development with multiple FDA designations. The company's strategy involves advancing its internal pipeline in infectious disease and inflammation while seeking partnerships to leverage its LNC platform across broader therapeutic areas, including oncology and oligonucleotide delivery.

About Matinas Biopharma

Matinas BioPharma's mission is to overcome critical drug delivery challenges through its Lipid Nano-Crystal (LNC) platform, which facilitates oral, intracellular delivery of complex therapeutics. Its primary achievement is the advancement of MAT2203, an oral formulation of the potent but toxic antifungal amphotericin B, into Phase 2/3 clinical development with multiple FDA designations. The company's strategy involves advancing its internal pipeline in infectious disease and inflammation while seeking partnerships to leverage its LNC platform across broader therapeutic areas, including oncology and oligonucleotide delivery.

About Matinas Biopharma

Matinas BioPharma's mission is to overcome critical drug delivery challenges through its Lipid Nano-Crystal (LNC) platform, which facilitates oral, intracellular delivery of complex therapeutics. Its primary achievement is the advancement of MAT2203, an oral formulation of the potent but toxic antifungal amphotericin B, into Phase 2/3 clinical development with multiple FDA designations. The company's strategy involves advancing its internal pipeline in infectious disease and inflammation while seeking partnerships to leverage its LNC platform across broader therapeutic areas, including oncology and oligonucleotide delivery.

Therapeutic Areas